Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 730

1.

Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.

Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC.

J Natl Cancer Inst. 2003 Nov 5;95(21):1586-97.

PMID:
14600091
2.

Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.

Osipo C, Gajdos C, Liu H, Chen B, Jordan VC.

J Natl Cancer Inst. 2003 Nov 5;95(21):1597-608.

PMID:
14600092
3.

Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.

O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2255-63.

4.

Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.

Osipo C, Gajdos C, Cheng D, Jordan VC.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):249-56.

PMID:
15860267
5.

Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature.

Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, Malaise M, Merville MP, Bours V, Franchimont N.

Mol Pharmacol. 2006 May;69(5):1615-23. Epub 2006 Feb 23.

6.

Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, Jordan VC.

Int J Oncol. 2005 Aug;27(2):327-35.

PMID:
16010412
7.

Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.

Rossi V, Bellastella G, De Rosa C, Abbondanza C, Visconti D, Maione L, Chieffi P, Della Ragione F, Prezioso D, De Bellis A, Bellastella A, Sinisi AA.

J Cell Physiol. 2011 May;226(5):1334-9. doi: 10.1002/jcp.22461.

PMID:
20945400
8.

Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, Grimshaw R, Jarman M, Dowsett M.

Cancer Res. 1999 Aug 1;59(15):3646-51.

9.

Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.

Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ.

J Natl Cancer Inst. 2001 Nov 21;93(22):1714-23.

PMID:
11717332
10.

Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.

Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, Fine HA.

Cancer Res. 2004 Dec 15;64(24):9115-23.

11.

Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells.

Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S, Sidi Y.

Cancer Invest. 2002;20(4):509-17.

PMID:
12094546
12.

Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.

Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC.

Clin Cancer Res. 2002 Jun;8(6):1995-2001.

14.

Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.

Scherbakov AM, Lobanova YS, Andreeva OE, Shatskaya VA, Krasil'nikov MA.

Biosci Rep. 2011 Apr;31(2):137-43. doi: 10.1042/BSR20100052.

PMID:
20662767
15.
16.

Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.

Gao ZO, Gao ZP, Fields JZ, Boman BM.

Anticancer Res. 2002 May-Jun;22(3):1379-83.

PMID:
12168814
17.

Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats.

Chung MT, Cheng PY, Lam KK, Chen SY, Ting YF, Yen MH, Lee YM.

Menopause. 2010 Jan-Feb;17(1):127-34. doi: 10.1097/gme.0b013e3181b4c4ac.

PMID:
19745773
18.

Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation.

Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, Kuo ML.

J Biol Chem. 2004 Jun 4;279(23):24015-23. Epub 2004 Mar 24.

19.

Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.

O'Regan RM, Gajdos C, Dardes RC, De Los Reyes A, Park W, Rademaker AW, Jordan VC.

J Natl Cancer Inst. 2002 Feb 20;94(4):274-83.

PMID:
11854389
20.

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.

Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D.

Anticancer Res. 2007 May-Jun;27(3B):1393-9.

Supplemental Content

Support Center